Skip to main content
NewslettersWatchlist

Dynavax Technologies(DVAX-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low10.92
Day High11.16
Open:11.05
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Motley Fool
Dynavax Technologies (DVAX) Q1 2024 Earnings Call Transcript
Motley Fool
Dynavax Technologies (DVAX) Q4 2023 Earnings Call Transcript
Motley Fool
Why Vera Therapeutics Stock Soared by 22% This Week
Motley Fool
Dynavax Technologies (DVAX) Q3 2023 Earnings Call Transcript
PR Newswire
Dynavax to Present at the H.C. Wainwright 4th Annual Hepatitis B Virus Virtual Conference
PR Newswire
Dynavax to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Motley Fool
Dynavax Technologies (DVAX) Q2 2023 Earnings Call Transcript
PR Newswire
Dynavax Reports Second Quarter 2023 Financial Results and Raises Full Year Revenue Guidance
PR Newswire
Dynavax to Report Second Quarter 2023 Financial Results and Host Conference Call on August 3, 2023
PR Newswire
Dynavax to Present at Upcoming Investor Conferences
PR Newswire
Dynavax to Present at the JMP Securities Life Sciences Conference
Motley Fool
Dynavax Technologies (DVAX) Q1 2023 Earnings Call Transcript
PR Newswire
Dynavax Reports First Quarter 2023 Financial Results
PR Newswire
Dynavax to Present at the Cowen 43rd Annual Health Care Conference
Motley Fool
Dynavax Technologies (DVAX) Q4 2022 Earnings Call Transcript
PR Newswire
Dynavax Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Full Year 2023 Financial Guidance
PR Newswire
Dynavax to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023
PR Newswire
Dynavax Announces Uplisting to the Nasdaq Global Select Market
PR Newswire
Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Financial Highlights and Phase 1 Shingles Topline Results
PR Newswire
Dynavax to Present at Two Upcoming Investor Conferences
Motley Fool
Dynavax Technologies (DVAX) Q3 2022 Earnings Call Transcript
PR Newswire
Dynavax Reports Third Quarter 2022 Financial Results
PR Newswire
Dynavax to Report Third Quarter Financial Results and Host Conference Call on November 3, 2022
PR Newswire
Dynavax to Present at the H.C. Wainwright 3rd Annual Hepatitis B Virus Virtual Conference
Motley Fool
Why Dynavax Stock Popped by Over 5% Today
PR Newswire
Dynavax Announces First Participant Dosed in a Phase 2 Clinical Trial Evaluating an Adjuvanted Plague Vaccine
PR Newswire
Dynavax to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Motley Fool
Dynavax Technologies (DVAX) Q2 2022 Earnings Call Transcript
Motley Fool
Why Dynavax Stock Was Crushing It on Friday
PR Newswire
Dynavax Reports Second Quarter 2022 Financial Results
PR Newswire
Dynavax to Report Second Quarter Financial Results and Host Conference Call on August 4, 2022
Motley Fool
Why Dynavax Crushed the Market on Thursday

Profile

Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax's clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.